Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1464 • ACR Convergence 2025
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Lara Gómez⁹, Kim Hoyt¹⁰, Weibin Bao¹¹ and Karl Gaffney¹², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Farmaceutica, Madrid, Spain, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹²Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…
Abstract Number: 1437 • ACR Convergence 2025
Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
Byron Kwan¹, Joseph Merola², Andrew Blauvelt³, Daniel Rios¹, Joana Ministro¹, Jacob Milligan¹, Ghassan Fayad¹, Christopher Finch⁴, Eugenia Levi⁵, Joseph Senn⁵, Jason Oh¹ and Hussam Shaheen¹, ¹Paragon Therapeutics, Waltham, MA, ²UT Southwestern Medical Center, Dallas, TX, ³Blauvelt Consulting, LLC, Annapolis, MD, ⁴Oruka Therapeutics, Menlo Park, CA, ⁵Oruka Therapeutics, Waltham, MA
Background/Purpose: Interleukin 17 (IL-17) is a pro-inflammatory cytokine that has been implicated in the pathogenesis of multiple autoimmune conditions, including psoriasis and psoriatic arthritis (PsA).…
Abstract Number: 1223 • ACR Convergence 2025
Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Alexis Ogdie¹, Astrid Rasmussen², Dana Orange³, Michelle Petri⁴, Caroline Shiboski⁵, Rebecca Haberman⁶, Mala Masson⁷, Daniel Goldman⁴, Peter Izmirly⁸, Brooke Cohen⁹, Jennifer Seifert¹⁰, Jennifer Anolik¹¹, Wade DeJager¹², Alan Baer¹³, Jill Buyon¹⁴ and Yvonne Lee¹⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³The Rockefeller University, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸New York University Grossman School of Medicine, New York, NY, ⁹Yale Physician Associate Program, New Haven, CT, ¹⁰University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ¹¹University of Rochester Medical Center, Rochester, NY, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵Northwestern University, Chicago, IL
Background/Purpose: The Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) network seeks to understand the cellular and molecular interactions that lead to inflammation and…
Abstract Number: 0575 • ACR Convergence 2025
Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
Laia De Daniel Bisbe¹, Jesús Rodriguez², Laura Berbel³, Joan Miquel Nolla¹, Aina Fabregat², Monica Cubells² and Diego Benavent Nuñez², ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital Universitari de Bellvitge, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease combining psoriasis (Pso) and arthritis. Despite the availability of multiple therapeutic options, many patients experience residual…
Abstract Number: 0874 • ACR Convergence 2025
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Atul Deodhar¹, Ricardo Blanco², Arthur Kavanaugh³, Alice Gottlieb⁴, Laura Coates⁵, Christopher Ritchlin⁶, Alan Kivitz⁷, Xiaofeng Zeng⁸, Akimichi Morita⁹, Diamant Thaçi¹⁰, Stefan Varga¹¹, Kexuan Li¹¹, Ying-Ming Jou¹², Eleni Vritzali¹³ and Philip J. Mease¹⁴, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³University of California, San Diego, School of Medicine, San Diego, CA, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁹Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol Myers Squibb, Boudry, Switzerland, ¹⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over…
Abstract Number: 0483 • ACR Convergence 2025
Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
Clara De Miguel¹, Héctor Vega², Marta Sánchez², Esther Toledano³, Pedro Pablo Bermejo⁴, Leonor Laredo⁵, José Alberto Peña⁶, María Teresa Benítez⁷, DALIFER FREITES⁸, LETICIA LEON⁹ and lydia Abasolo Alcazar¹⁰, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Complutense University of Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ⁴Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁶Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁷San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ¹⁰IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) are chronic inflammatory arthritis (CIAs). Janus kinase inhibitors (JAKis) have emerged as a promising therapeutic…
Abstract Number: 0105 • ACR Convergence 2025
Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
Guillaume LARID¹, Cassandre Dumonteix Moreau², Adrien JAMAI², Hanitriniaina Rabeony², Jean Claude LECRON², Elisabeth Gervais¹, Jean François JEGOU² and franck MOREL², ¹Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ²Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France
Background/Purpose: Psoriatic disease is a systemic inflammatory condition which encompasses both cutaneous psoriasis (PsO), psoriatic arthritis (PsA) and multiple comorbidities. The chronic Imiquimod (IMQ) induced…
Abstract Number: 0220 • ACR Convergence 2024
Ultrasound-assessed Dactylitis as a Biomarker in the Early Diagnosis of Psoriatic Arthritis
Otto Olivas-Vergara¹, Raquel Largo², Lina Martínez-Estupiñán³, Fredeswinda Romero-Bueno⁴, Olga Sánchez-Pernaute³, Javier R. Godo³, Maria del Carmen Fariña-Sabaris⁵, Belen Ruffin Vicente⁵, Carmen Herencia⁶, Aránzazu Mediero², Agustina Criado Alcazar⁷, Pablo E. Borges¹, Sheila Recuero-Díaz¹, Andrea Alvear-Torres³, Amalia Gil³, Antía García-Fernández³, Ana Elena Hoyo Fernandez⁸, M. Isabel Sanchez-Barba⁸, M. Belen Ortega Trompeta⁸, Cristina Vazquez-Carballo⁹, Gabriel Herrero-Beaumont³ and ESPERANZA NAREDO¹⁰, ¹Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ²Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, ³Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁴Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁵Department of Dermatology.Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁶Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, ⁷Primary Care..Centro de Salud Paseo Imperial, Madrid, Spain, ⁸Primary Care.Centro de Salud Paseo Imperial, Madrid, Spain, ⁹Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz. Autonomous University of Madrid, Madrid, Spain, ¹⁰Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The primary objective of this prospective, longitudinal, observational study was to evaluate the predictive value of ultrasound (US)-detected elementary lesions of dactylitis together with…
Abstract Number: 0583 • ACR Convergence 2024
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
Alexis Ogdie¹, Philip Mease², Francois Nantel³, Frederic Lavie⁴, Mohamed Sharaf⁵, Emmanouil Rampakakis⁶, Helena Marzo-Ortega⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Nantel MedSci Consult, Montreal, QC, Canada, ⁴Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸Sorbonne Université, Paris, France
Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…
Abstract Number: 0604 • ACR Convergence 2024
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Mahum Mirza¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
Abstract Number: 1229 • ACR Convergence 2024
Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study
avin maroof¹, Nelly Ziade², Lina El Kibbi³, Bassel Elzorkany⁴, Nizar Ani⁵, ASAL ADNAN RIDHA⁶, Faiq Gorial⁷, NABAA IHSAN JAWAD AWADH⁸, Nada Al Chama⁹, Chafika Haouichat¹⁰, Fatima Alnaimat¹¹, Suad Mohamed Abdulla Hannawi¹², Suad Hannawi¹³, Saed Atawnah¹⁴, HUSSEIN HALABI¹⁵, Manal Al-Mashaleh¹⁶, Ahmed Abogamal¹⁷, Rachid Bahiri¹⁸, Sahar Saad¹⁹, maha sabkar²⁰, Krystel Aouad²¹, Laure Gossec²², Ihsane Hmamouchi²³, nabaa abbas²⁴, Elyes Bouajina²⁵, Laila Aljazye²⁶ and Laila ayoub²⁷, and ArLAR-ARCH group, ¹University of Kurdistan Hawler, Erbil, Iraq, ²Saint-Joseph University, Beirut, Lebanon, ³Division of rheumatology / Department of Medicine / Specialized Medical Center, Riyadh, Saudi Arabia, ⁴Private (BZRC), Cairo, Egypt, ⁵Baghdad College of Medicine, Baghdad, Iraq, ⁶Baghdad Teaching Hospital, baghdad, Iraq, ⁷Rheumatology Unit/Department of Medicine/ College of Medicine/ University of Baghdad, Baghdad, Iraq, ⁸Baghdad Teaching Hospital / Medical City, Baghdad, Iraq, ⁹Rheumatology Department / Ebn Al Nafiss Hospital / Damascus, Damascus, Syria, ¹⁰Djillali Bounaama university hospital, Algiers, Algeria, ¹¹The University of Jordan, amman, Jordan, ¹²Rheymatology Department / Emirate Health Services / Dubai, Dubai, United Arab Emirates, ¹³Ministry of Health and Prevention, Dubai, United Arab Emirates, ¹⁴Al-Quds University / Alahli Hospital / Hebron ,Palestine, Hebron, Palestinian Territories, ¹⁵King Faisal Specialist Hospital / Jeddah, Jeddah, Saudi Arabia, ¹⁶Royal Medical Services, Amman, Jordan, ¹⁷Dr. Sliman Al Habib Hospital / Al-Azhar Faculty of Medicine, Dubai, United Arab Emirates, ¹⁸El Ayachi Hospital / Medical University Hospital / Rabat, Rabat, Morocco, ¹⁹King Hamad University Hospital / Assiut Medical School of Egypt, Al Sayh, Bahrain, ²⁰King Hamad university Hospital, Arad, Bahrain, ²¹Saint George Hospital University Medical Center, Beirut, Lebanon, ²²Sorbonne Université, Paris, France, ²³Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ²⁴Baghdad teaching hospital, Medical city, Baghdad, Iraq, Baghdad, Iraq, ²⁵Farhat Hached Hospital of Sousse, Tunisia, Sousse, Tunisia, ²⁶Tripoli / Libya, Tripoli, Libya, ²⁷Rheumatology unit, department of internal medicine, Tripoli Central Hospital. Faculty of Medicine, University of Tripoli, Libya, Tripoli, Libya
Background/Purpose: Fibromyalgia (FM), a chronic pain disorder, is more prevalent in psoriatic arthritis (PsA) patients, impacting quality of life and potentially leading to unnecessary treatment escalation. Cultural factors may…
Abstract Number: 1462 • ACR Convergence 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Philip Mease¹, Ruizhi Zhao², Shannon Ferrante³, Natalie J. Shiff⁴, Pavithra Srinivas⁵, Soumya Chakravarty⁶ and Jessica A Walsh⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs LLC, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 2311 • ACR Convergence 2024
Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans
Natalie Anumolu¹, Ann Rosenthal¹, Katherine Sherman² and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee
Background/Purpose: CPPD has been shown to complicate other types of inflammatory arthritis such as rheumatoid arthritis. However, only a few studies have investigated the correlation…
Abstract Number: 2328 • ACR Convergence 2024
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
Fadi Kharouf¹, Virginia Carrizo Abarza², Shangyi Gao³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].